top of page

The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC

Wed, Dec 12

|

Joey's Bar & Grill

Verzenio is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) advanced or metastatic breast cancer (MBC)

Registration is Closed
See other events
The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC
The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC

Time & Location

Dec 12, 2018, 5:30 PM

Joey's Bar & Grill, 344 Chandler St, Worcester, MA 01602, USA

Guests

About The Event

Speaker:

Blanca Ledezema, APN, APNP, MN, MS, NP

UCLA Hematology Oncology Santa Monica, CA

Description:

This program will present efficacy and safety data for Verzenio, a CDK4 + CDK6 inhibitor approved in comibination with fluvestrant, in combination with an Al, and as a single age for HR+, HER2- advanced or MMBC. Information about mechanism of action and dosing will also be presented.

Program Objectives:

Share This Event

BONS logo.png

Contact:

Daunielle Ricardi, President

Alissa Gentile, Treasurer

Cameron Keith, Social Media Coordinator

Email: BonsSocialMedia@gmail.com

  • Facebook
  • Instagram
  • LinkedIn
Earthen Media-4.png
bottom of page